We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+5.2%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$250M
AUM Growth
+$56M
Cap. Flow
+$44.7M
Cap. Flow %
17.87%
Top 10 Hldgs %
51.39%
Holding
108
New
15
Increased
21
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.19M
2
MU icon
Micron Technology
MU
+$1.73M
3
C icon
Citigroup
C
+$1.45M
4
URNM icon
Sprott Uranium Miners ETF
URNM
+$1.1M
5
AMGN icon
Amgen
AMGN
+$818K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.95M
2
AAPL icon
Apple
AAPL
+$2.23M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$1.15M
4
GLD icon
SPDR Gold Trust
GLD
+$916K
5
BHVN icon
Biohaven
BHVN
+$805K

Sector Composition

Rank Sector Weight
1 Healthcare 26.92%
2 Technology 16.18%
3 Communication Services 7.16%
4 Consumer Discretionary 6.33%
5 Financials 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRCX icon
76
Lam Research
LRCX
$367B
$408K 0.16%
5,000
– –
ALT icon
77
CALL
Altimmune
ALT
$552M
$350K 0.14%
57,000
-51,000
-47% -$346K
PANW icon
78
Palo Alto Networks
PANW
$270B
$342K 0.14%
2,000
– –
VRDN icon
79
Viridian Therapeutics
VRDN
$2.09B
$330K 0.13%
14,500
-3,250
-18% -$53.1K
MEOH icon
80
Methanex
MEOH
$4.3B
$310K 0.12%
+7,500
New +$335K
MU icon
81
CALL
Micron Technology
MU
$930B
$259K 0.1%
+2,500
New +$261K
ALT icon
82
Altimmune
ALT
$552M
$233K 0.09%
37,868
-5,000
-12% -$33.9K
T icon
83
AT&T
T
$159B
$224K 0.09%
10,200
-37,500
-79% -$746K
NOK icon
84
Nokia
NOK
$51B
$219K 0.09%
50,000
– –
WOLF icon
85
Wolfspeed
WOLF
$1.23B
$200K 0.08%
20,600
– –
IONS icon
86
CALL
Ionis Pharmaceuticals
IONS
$8.6B
$160K 0.06%
4,000
+3,500
+700% +$163K
C icon
87
CALL
Citigroup
C
$222B
$157K 0.06%
+2,500
New +$155K
NN icon
88
NextNav
NN
$1.79B
$127K 0.05%
+17,000
New +$131K
RVNC
89
DELISTED
Revance Therapeutics, Inc.
RVNC
$101K 0.04%
19,417
-230,583
-92% -$1.15M
GDX icon
90
CALL
VanEck Gold Miners ETF
GDX
$22.7B
$99.5K 0.04%
+2,500
New +$94.7K
LCTX icon
91
Lineage Cell Therapeutics
LCTX
$269M
$97.5K 0.04%
107,751
– –
TBHC
92
DELISTED
The Brand House Collective
TBHC
$55.7K 0.02%
25,415
– –
RPRX icon
93
CALL
Royalty Pharma
RPRX
$25.9B
$28.3K 0.01%
+1,000
New +$27.7K
EQ icon
94
Equillium
EQ
$139M
$27.4K 0.01%
32,962
– –
OVID icon
95
Ovid Therapeutics
OVID
$414M
$17.4K 0.01%
14,750
-27,000
-65% -$28.2K
BHVN icon
96
PUT
Biohaven
BHVN
$2.03B
– –
-1,500
Closed -$52.1K
BIIB icon
97
Biogen
BIIB
$30B
– –
-1,000
Closed -$232K
DE icon
98
CALL
Deere & Co
DE
$160B
– –
-800
Closed -$299K
ESPR
99
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-250
Closed -$555
IOT icon
100
Samsara
IOT
$21.7B
– –
-10,000
Closed -$337K
1 2 3
4
5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, DCF Advisers held 108 positions worth $250M, up 29% from $194M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DCF Advisers deployed $44.7M of net new capital in Q3 2024, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was NewAmsterdam Pharma: 34,000 shares worth $564K.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 34% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.95M trimmed.

  • DCF Advisers's largest Q3 2024 buy was NewAmsterdam Pharma: 34,000 shares worth $564K.
  • DCF Advisers added most to Amazon in Q3 2024, an estimated $3.19M increase.
  • DCF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.95M.
  • DCF Advisers fully exited Snowflake in Q3 2024, selling an estimated $439K.
  • DCF Advisers's ten largest holdings make up 51% of its $250M portfolio in Q3 2024.
  • DCF Advisers opened 15 new positions and closed 11 in Q3 2024.
  • DCF Advisers's portfolio value rose 29% quarter-over-quarter to $250M.

Based on DCF Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.